Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01731002 |
Recruitment Status
:
Completed
First Posted
: November 21, 2012
Results First Posted
: April 17, 2018
Last Update Posted
: April 17, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ocular Hypertension Open Angle Glaucoma | Drug: AR-13324 Ophthalmic Solution 0.01% Drug: AR-13324 Ophthalmic Solution 0.02% Drug: Latanoprost ophthalmic solution 0.005% | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 224 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure |
Study Start Date : | November 2012 |
Actual Primary Completion Date : | May 2013 |
Actual Study Completion Date : | May 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: AR-13324 Ophthalmic Solution 0.01%
1 drop to study eye once daily
|
Drug: AR-13324 Ophthalmic Solution 0.01%
Administered to study eye, once daily (QD) in the evening (PM) for 28 days
|
Experimental: AR-13324 Ophthalmic Solution 0.02%
1 drop to study eye once daily
|
Drug: AR-13324 Ophthalmic Solution 0.02%
Administered to study eye, QD in the PM for 28 days
Other Name: Netarsudil
|
Active Comparator: Latanoprost Ophthalmic Solution 0.005%
1 drop to study eye once daily
|
Drug: Latanoprost ophthalmic solution 0.005%
Administered to study eye, QD in the PM for 28 days
Other Name: Latanoprost
|
- Intraocular Pressure (IOP) [ Time Frame: Study treatment was administered for 28 days ]The primary efficacy endpoint was the mean IOP across subjects within treatment group on each day at each post-treatment timepoint. IOP was measured at 0800, 1000, and 1600 hours on days 0, 14, and 28. IOP was also measured at 0800 hours on Day 7 and follow-up days 29 and 30.
- Extent of Exposure [ Time Frame: 28 Days ]Exposure to study medication in days for all treatment groups.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or greater.
- Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Unmedicated (post-washout) Intraocular Pressure (IOP) ≥ 24 mm Hg at 2 eligibility visits (08:00 hr), 2-7 days a part, and ≥ 22 mm Hg at 10:00 and 16:00 hrs at the second qualification visit. If only one eye meets the IOP criteria it must be the same eye that met the criteria at all the qualification timepoints.
- Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- Able and willing to give signed informed consent and follow study instructions.
Exclusion Criteria:
Ophthalmic
- Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
- IOP > 36 mm Hg.
- Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s, e.g., laser trabeculoplasty).
- Refractive surgery in study eye(s) (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser eye surgery (LASIK), etc.).
- Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months prior to screening.
- Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at screening (Visit 0), or a history of herpes simplex keratitis
- Ocular medication of any kind within 30 days of Visit 0, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 0) or c) lubricating drops for dry eye (which may be used throughout the study).
- Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (i.e., cup-disc ratio > 0.8).
- Central corneal thickness greater than 600 µm.
-
Any abnormality preventing reliable applanation tonometry of either eye.
Systemic:
- Clinically significant abnormalities (as determined by the treating physician) in laboratory tests at screening.
- Known hypersensitivity or contraindication to latanoprost.
- Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- Participation in any investigational study within 30 days prior to screening.
- Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
- Due to the current status of the preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731002
United States, California | |
Kenneth Sall, M.D. | |
Artesia, California, United States, 90701 | |
United Medical Research Institute | |
Inglewood, California, United States, 90301 | |
Aesthetic Eye Care Institute | |
Newport Beach, California, United States, 92657 | |
North Bay Eye Associates | |
Petaluma, California, United States, 94954 | |
Centre For Health Care | |
Poway, California, United States, 92064 | |
United States, Georgia | |
Clayton Eye Center | |
Morrow, Georgia, United States, 30260 | |
Coastal Research Associates, LLC | |
Roswell, Georgia, United States, 30076 | |
United States, Kansas | |
Bradley Kwapiszeski, MD | |
Shawnee Mission, Kansas, United States, 66204 | |
United States, Kentucky | |
Taustine Eye Center | |
Louisville, Kentucky, United States, 40217 | |
United States, Maryland | |
Alan L Robin, M.D. | |
Baltimore, Maryland, United States, 21209 | |
Seidenberg Protzko Eye Associates | |
Havre De Grace, Maryland, United States, 21078 | |
United States, Michigan | |
Great Lakes Eye Care | |
Saint Joseph, Michigan, United States, 49085 | |
United States, New York | |
Ophthalmic Consultants of Long Island | |
Lynbrook, New York, United States, 11563 | |
Rochester Ophthalmological Group | |
Rochester, New York, United States, 14618 | |
United States, North Carolina | |
Charlotte Eye Ear Nose and Throat | |
Charlotte, North Carolina, United States, 28210 | |
Michael E. Tepedino, M.D. | |
High Point, North Carolina, United States, 27262 | |
United States, Oklahoma | |
The Eye Institute | |
Tulsa, Oklahoma, United States, 74104 | |
United States, Pennsylvania | |
Wills Eye Hospital | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, Texas | |
Texan Eye | |
Austin, Texas, United States, 78731 | |
Cataract & Glaucoma Center | |
El Paso, Texas, United States, 79902 | |
Medical Center Ophth. Associates | |
San Antonio, Texas, United States, 78731 | |
United States, Virginia | |
Virginia Eye Consultants | |
Norfolk, Virginia, United States, 23502 |
Study Director: | Theresa Heah, MD | Aerie Pharmaceuticals, Inc. |
Responsible Party: | Aerie Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01731002 History of Changes |
Other Study ID Numbers: |
AR-13324-CS202 |
First Posted: | November 21, 2012 Key Record Dates |
Results First Posted: | April 17, 2018 |
Last Update Posted: | April 17, 2018 |
Last Verified: | June 2016 |
Keywords provided by Aerie Pharmaceuticals:
Glaucoma |
Additional relevant MeSH terms:
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases |
Pharmaceutical Solutions Ophthalmic Solutions Latanoprost Antihypertensive Agents |